FDA panel will review drug-associated suicidality study
Executive Summary
FDA will discuss the results of its analysis of suicidality from placebo-controlled trials of 11 drugs at a joint advisory committee meeting, which could lead to broad class labeling changes. Members of the Peripheral and Central Nervous System Drugs, Psychopharmacological Drugs, Pediatric, and Drug Safety and Risk Management Advisory Committees will meet July 10 to consider the analysis and determine whether any additional actions are necessary. Findings of increased risk of suicidality in patients taking antiepileptic drugs were noted in a MedWatch alert issued in January (1"The Pink Sheet," Feb. 4, 2008, p. 3)
You may also be interested in...
Antiepileptics Show Risk Of Suicidality, May Cause Labeling Convulsions
FDA findings of an increased risk of suicidality in patients given antiepileptic drugs will likely lead to broad class labeling changes, according to a MedWatch alert issued Jan. 31
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.